NO20052987L - Forbindelser for normalisering av sovn/vaken-syklusen. - Google Patents
Forbindelser for normalisering av sovn/vaken-syklusen.Info
- Publication number
- NO20052987L NO20052987L NO20052987A NO20052987A NO20052987L NO 20052987 L NO20052987 L NO 20052987L NO 20052987 A NO20052987 A NO 20052987A NO 20052987 A NO20052987 A NO 20052987A NO 20052987 L NO20052987 L NO 20052987L
- Authority
- NO
- Norway
- Prior art keywords
- sleep
- compound
- methods
- normalizing
- containing compound
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 6
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 abstract 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 abstract 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 abstract 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 abstract 2
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 abstract 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 abstract 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 206010028347 Muscle twitching Diseases 0.000 abstract 1
- 206010062519 Poor quality sleep Diseases 0.000 abstract 1
- 208000005793 Restless legs syndrome Diseases 0.000 abstract 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 abstract 1
- 208000032140 Sleepiness Diseases 0.000 abstract 1
- 206010041349 Somnolence Diseases 0.000 abstract 1
- 229960005305 adenosine Drugs 0.000 abstract 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 abstract 1
- 230000003920 cognitive function Effects 0.000 abstract 1
- 229960003624 creatine Drugs 0.000 abstract 1
- 239000006046 creatine Substances 0.000 abstract 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 abstract 1
- 229940104302 cytosine Drugs 0.000 abstract 1
- 206010022437 insomnia Diseases 0.000 abstract 1
- 201000003631 narcolepsy Diseases 0.000 abstract 1
- 230000000737 periodic effect Effects 0.000 abstract 1
- 201000002859 sleep apnea Diseases 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 230000003860 sleep quality Effects 0.000 abstract 1
- 230000037321 sleepiness Effects 0.000 abstract 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 abstract 1
- 229940045145 uridine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43545702P | 2002-12-20 | 2002-12-20 | |
| PCT/US2003/040450 WO2004058160A2 (en) | 2002-12-20 | 2003-12-17 | Compounds for the normalization of the sleep/wake cycle |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20052987D0 NO20052987D0 (no) | 2005-06-17 |
| NO20052987L true NO20052987L (no) | 2005-08-29 |
Family
ID=32682243
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20052987A NO20052987L (no) | 2002-12-20 | 2005-06-17 | Forbindelser for normalisering av sovn/vaken-syklusen. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20040176316A1 (ru) |
| EP (1) | EP1589979A4 (ru) |
| JP (2) | JP4717444B2 (ru) |
| CN (1) | CN100563660C (ru) |
| AU (1) | AU2003299715A1 (ru) |
| BR (1) | BR0317586A (ru) |
| CA (1) | CA2508995A1 (ru) |
| MX (1) | MXPA05006781A (ru) |
| NO (1) | NO20052987L (ru) |
| RU (1) | RU2366428C2 (ru) |
| UA (1) | UA88869C2 (ru) |
| WO (1) | WO2004058160A2 (ru) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2425114T3 (es) * | 2000-03-16 | 2013-10-11 | The Mclean Hospital Corporation | CDP-colina y uridina para el tratamiento del abuso del acohol |
| EP1565055B1 (en) * | 2002-11-08 | 2013-06-12 | THE McLEAN HOSPITAL CORPORATION | Compounds for the treatment of tobacco dependence and withdrawal |
| US20050113449A1 (en) * | 2003-10-08 | 2005-05-26 | Renshaw Perry F. | Enhanced efficacy of omega-3 fatty acid therapy in the treatment of psychiatric disorders and other indications |
| CA2542023A1 (en) * | 2003-10-08 | 2005-09-22 | The Mclean Hospital Corporation | Methods of treating psychiatric, substance abuse, and other disorders using combinations containing omega-3 fatty acids |
| EP1765364A4 (en) * | 2004-06-10 | 2010-09-22 | Mclean Hospital Corp | PYRIMIDINES, SUCH AS Z: B: CYTIDINE, IN THE TREATMENT OF PATIENTS WITH BIPOLAR DISORDER |
| WO2005122767A1 (en) * | 2004-06-10 | 2005-12-29 | Mclean Hospital Corporation | Pyrimidines, such as uridine, in treatments for patients with bipolar disorder |
| EP1784199A4 (en) * | 2004-08-11 | 2010-06-23 | Mclean Hospital Corp | COMPOUNDS FOR TREATING MARIHUANA DEPENDENCE, DEDUCTION AND CONSUMPTION |
| PL1888081T3 (pl) * | 2005-05-23 | 2017-07-31 | Massachusetts Institute Of Technology | Kompozycje zawierające PUFA i sposoby ich zastosowania |
| TW200827367A (en) * | 2006-10-26 | 2008-07-01 | Kyowa Hakko Kogyo Kk | A therapeutic agent for irritable bowel syndrome |
| AU2008322414C1 (en) * | 2007-11-16 | 2014-05-01 | International Ip Holdings Llc | Edible energy composition with low caffeine |
| US20100041621A1 (en) * | 2008-08-15 | 2010-02-18 | Perry Renshaw | Methods and compositions for improving cognitive performance |
| JP5426918B2 (ja) * | 2009-04-20 | 2014-02-26 | 株式会社 伊藤園 | ウリジンを含有する抗疲労剤又は体力向上剤 |
| JP2011032232A (ja) * | 2009-08-04 | 2011-02-17 | Ito En Ltd | 興奮抑制用又は鎮静用組成物及びこれを含む飲食品 |
| JP5989319B2 (ja) | 2011-10-06 | 2016-09-07 | ライオン株式会社 | 睡眠の質改善剤 |
| JP6165852B2 (ja) * | 2012-06-04 | 2017-07-19 | ファイザー・インク | 睡眠障害を治療するためのグレリン受容体逆アゴニストまたはアンタゴニストの使用 |
| KR102245628B1 (ko) * | 2013-04-05 | 2021-04-28 | 라이온 가부시키가이샤 | 내복 조성물 |
| EP3056096B1 (de) * | 2015-02-05 | 2019-07-24 | Smart Sleep GmbH | Verwendung eines Nahrungsergänzungsmittels enthaltend Kreatin zur Reduktion des natürlichen Schlafbedarfs oder zur schnelleren Anpassung der zirkadianen Rhythmik an neue Zeitzonen |
| EP3391886A1 (en) | 2017-04-19 | 2018-10-24 | Novartis AG | The use of a h3r inverse agonist for the treatment of shift work disorder |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4048316A (en) * | 1974-03-04 | 1977-09-13 | Penn Nathar W | Composition for antagonizing the narcotic effects of barbiturate addiction and withdrawal effects, and for treatment of barbiturate poisoning |
| US4115576A (en) * | 1974-04-02 | 1978-09-19 | Penn Nathar W | Compositions and method of employing the same for inhibiting alcohol intoxication |
| US4027017A (en) * | 1974-07-16 | 1977-05-31 | Chugai Seiyaku Kabushiki Kaisha | Method of treating alcoholism |
| IT1200589B (it) * | 1985-02-14 | 1989-01-27 | Gibipharma Spa | Derivati naturali attivita farmagologica |
| JPS63208524A (ja) * | 1987-02-25 | 1988-08-30 | Nippon Oil & Fats Co Ltd | 睡眠リズム改善剤 |
| US5691320A (en) * | 1987-10-28 | 1997-11-25 | Pro-Neuron, Inc. | Acylated pyrimidine nucleosides for treatment of systemic inflammation and inflammatory hepatitis |
| JPH0418034A (ja) * | 1990-05-11 | 1992-01-22 | Kanegafuchi Chem Ind Co Ltd | 点眼組成物 |
| US5635486A (en) * | 1990-05-11 | 1997-06-03 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Ophthalmic composition comprising a sleep adjusting substance |
| PT100525B (pt) * | 1991-05-29 | 1999-10-29 | Abbott Lab | Azaspiranos substituidos imunomodulares, seu uso e composicoes farmaceuticas que os contem |
| US5704361A (en) * | 1991-11-08 | 1998-01-06 | Mayo Foundation For Medical Education And Research | Volumetric image ultrasound transducer underfluid catheter system |
| US5278176A (en) * | 1992-08-21 | 1994-01-11 | Abbott Laboratories | Nicotine derivatives that enhance cognitive function |
| US5472958A (en) * | 1994-08-29 | 1995-12-05 | Abbott Laboratories | 2-((nitro)phenoxymethyl) heterocyclic compounds that enhance cognitive function |
| AU4070597A (en) * | 1996-08-16 | 1998-03-06 | The Texas A & M University System | Modifying insect cell gylcosylation pathways with baculovirus expression vectors |
| GB9623859D0 (en) * | 1996-11-15 | 1997-01-08 | Chiroscience Ltd | Novel compounds |
| US5958896A (en) * | 1997-08-08 | 1999-09-28 | The Mclean Hospital | Cytidine-containing and cytosine-containing compounds as treatments for stimulant exposure |
| US5977174A (en) * | 1997-11-26 | 1999-11-02 | Neuromedica, Inc. | Cholinergic compositions and uses thereof |
| US6153653A (en) * | 1997-11-26 | 2000-11-28 | Protarga, Inc. | Choline compositions and uses thereof |
| WO2000006174A1 (en) * | 1998-07-31 | 2000-02-10 | Massachusetts Institute Of Technology | Methods for increasing cytidine levels in vivo and treating cytidine-dependent human diseases |
| DE19929995B4 (de) * | 1999-06-30 | 2004-06-03 | Skw Trostberg Ag | Verwendung von Kreatin und/oder Kreatin-Derivaten zur Behandlung von Befindlichkeitsstörungen bei Frauen |
| ES2425114T3 (es) * | 2000-03-16 | 2013-10-11 | The Mclean Hospital Corporation | CDP-colina y uridina para el tratamiento del abuso del acohol |
| ES2170649B1 (es) * | 2000-03-29 | 2003-06-16 | Ferrer Int | Uso de la cdp-colina en el tratamiento de la abstinencia alcoholica. |
| US6277855B1 (en) * | 2000-04-21 | 2001-08-21 | Inspire Pharmaceuticals, Inc. | Method of treating dry eye disease with nicotinic acetylcholine receptor agonists |
| US6964969B2 (en) * | 2001-04-19 | 2005-11-15 | Mccleary Edward Larry | Composition and method for treating impaired or deteriorating neurological function |
| US20030114415A1 (en) * | 2001-12-14 | 2003-06-19 | Wurtman Richard J. | Compositions and methods for treating and preventing memory impairment using citicoline |
-
2003
- 2003-12-17 BR BR0317586-3A patent/BR0317586A/pt not_active IP Right Cessation
- 2003-12-17 WO PCT/US2003/040450 patent/WO2004058160A2/en active Application Filing
- 2003-12-17 US US10/740,075 patent/US20040176316A1/en not_active Abandoned
- 2003-12-17 JP JP2004563786A patent/JP4717444B2/ja not_active Expired - Fee Related
- 2003-12-17 EP EP03799995A patent/EP1589979A4/en not_active Withdrawn
- 2003-12-17 AU AU2003299715A patent/AU2003299715A1/en not_active Abandoned
- 2003-12-17 RU RU2005122934/14A patent/RU2366428C2/ru not_active IP Right Cessation
- 2003-12-17 CA CA002508995A patent/CA2508995A1/en not_active Abandoned
- 2003-12-17 UA UAA200506506A patent/UA88869C2/ru unknown
- 2003-12-17 CN CNB2003801098191A patent/CN100563660C/zh not_active Expired - Fee Related
- 2003-12-17 MX MXPA05006781A patent/MXPA05006781A/es unknown
-
2005
- 2005-06-17 NO NO20052987A patent/NO20052987L/no not_active Application Discontinuation
-
2011
- 2011-01-17 JP JP2011006614A patent/JP2011102319A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP4717444B2 (ja) | 2011-07-06 |
| RU2005122934A (ru) | 2006-01-20 |
| MXPA05006781A (es) | 2005-09-30 |
| US20040176316A1 (en) | 2004-09-09 |
| EP1589979A2 (en) | 2005-11-02 |
| JP2011102319A (ja) | 2011-05-26 |
| BR0317586A (pt) | 2005-11-22 |
| CN100563660C (zh) | 2009-12-02 |
| EP1589979A4 (en) | 2009-04-01 |
| CN1750833A (zh) | 2006-03-22 |
| CA2508995A1 (en) | 2004-07-15 |
| RU2366428C2 (ru) | 2009-09-10 |
| AU2003299715A8 (en) | 2004-07-22 |
| JP2006513214A (ja) | 2006-04-20 |
| WO2004058160A3 (en) | 2005-03-31 |
| NO20052987D0 (no) | 2005-06-17 |
| UA88869C2 (ru) | 2009-12-10 |
| WO2004058160A2 (en) | 2004-07-15 |
| AU2003299715A1 (en) | 2004-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20052987L (no) | Forbindelser for normalisering av sovn/vaken-syklusen. | |
| DE60215919D1 (de) | 4-fluoro-n-indan-2-yl benzamid und seine verwendung als arzneimittel | |
| NZ533861A (en) | Proline compounds as NS3-serine protease inhibitors for use in treatment of hepatitis C virus infection | |
| DE69418601D1 (de) | Guanidinderivate mit therapeutischer wirkung | |
| EA200400881A1 (ru) | Азаарилпиперазины | |
| EA199900669A1 (ru) | Промежуточные соединения для получения замещенных n-[аминоиминометил или аминометил)фенил]пропиламидов | |
| EA200401478A1 (ru) | Монооксид углерода в качестве биомаркера и лекарственного средства | |
| NO20065079L (no) | Materialer og metoder for behandling av koaguleringssykdommer | |
| NO20043548L (no) | Anvendelse av flerumettede katoner for behandling av psoriasis | |
| WO2004024088A3 (en) | Design of chemokine analogs for the treatment of human diseases | |
| NO20002218D0 (no) | Anvendelse av mirtazepin for behandling av søvnapne | |
| PT1261333E (pt) | Utilizacao de topiramato para o tratamento e diagnostico de transtorno do sono relacionado com a respiracao e meios para realizar o metodo e o diagnostico | |
| TW200509929A (en) | Treatment of bipolar disorders and associated symptoms | |
| NO920395L (no) | Terapeutisk aktive benzyloksyfenyl-derivater og fremgangsmaate for deres fremstilling | |
| ATE421313T1 (de) | Verwendung einer dihydrochalcon-reichen phenolischen fraktion für eine kosmetische behandlung | |
| EE200200337A (et) | Uued ühendid ning nende kasutamine | |
| WO2001089536A3 (en) | Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders | |
| ATE406887T1 (de) | R-bambuterol, seine herstellung und therapeutische verwendungen | |
| ATE210980T1 (de) | Verwendung von indolderivaten zur behandlung von dermatologischen krankheiten, peridhren neuropathien, arthritis, allergischen oder chronisch-obstruktiven atemwegserkrankungen, glaukom und augenentzündungen | |
| CY1107756T1 (el) | Αναλογα θειου της 21-υδροξυ-6, 19-οξειδοπρογεστερονης (21oh-6οp) για τη θεραπεια πλεονασματος γλυκοκορτικοειδων | |
| EP1495755B8 (fr) | Utilisation de la citrulline dans la fabrication d'un médicament pour le traitement de l'insuffisance intestinale liée au vieillissement ou à une irradiation | |
| NO20024381L (no) | Preparat for anvendelse ved behandling av okular hypertensjon og gluakom | |
| DK1399142T3 (da) | Anvendelse af acetyl-L-carnitin i kombination med biotin til behandlingen af patienter med type-2 insulinresistent diabetes mellitus | |
| ATE382367T1 (de) | Behandlung des typ 1 diabetes vor und nach expression von prädispositionsmarkern | |
| WO2020264201A8 (en) | Lemborexant for treating sleep issues |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |